|- candidate number||2110|
|- NTR Number||NTR696|
|- Date ISRCTN created||26-feb-2007|
|- date ISRCTN requested||21-feb-2007|
|- Date Registered NTR||30-mei-2006|
|- Secondary IDs||N/A |
|- Public Title||Pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in healthy volunteers.|
|- Scientific Title||PK/PD study on S(+)-ketamine.|
|- ACRONYM||KET study.|
|- hypothesis||We will investigate the relationship between S(+)-ketamine plasmaconcentrations and its analgesic effect to estimates the onset/offset times of ketamine and potency parameters for various analgesia tests. This will allow the safer administration of S(+) ketamine in clinical practice.|
|- Healt Condition(s) or Problem(s) studied||Ketamine , Analgesic|
|- Inclusion criteria||1. Healthy volunteers 18+.|
|- Exclusion criteria||1. Obesity (BMI > 30);
2. Presence of medical disease (heart-, lung-, liver-, kidney-, neurologic disease; diabetes m.; pyrosis; diaphragmatic hernia);
3. Presence of psychiatric disease;
4. History of chronic alcohol or drug use;
5. Allergy to study medications;
6. Possibility of pregnancy and
|- mec approval received||no|
|- multicenter trial||no|
|- planned startdate ||1-feb-2007|
|- planned closingdate||1-feb-2008|
|- Target number of participants||24|
|- Interventions||Infusion of S(+)-ketamine or placebo.
The are three infusion schemes:
I. In four subjects there will be two 30-min infusions of S(+)-ketamine, separated by 30-min of no-infusion (end of infusion is at t = 90 min).
II. In four subjects there will be five 10-min infusions of (S)+-ketamine, all separated by 10-min of no-infusion (end-of infusion is at t = 90 min).
III. In four subjects there will be three 20-min infusions of S(+)-ketamine, all separated by 20-min of no-infusion (end of infusions is at t = 100 min).
IV. As I, but now placebo (NaCl 0.9%) will be infused.
V. As II, but now placebo (NaCl 0.9%) will be infused.
VI. As III, , but now placebo (NaCl 0.9%) will be infused.
|- Primary outcome||Analgesia and Plasma Cp of ketamine.|
|- Secondary outcome||Bowdle scale parameters.|
|- Trial web site||N/A|
|- CONTACT FOR PUBLIC QUERIES||Prof. Dr. Albert Dahan|
|- CONTACT for SCIENTIFIC QUERIES||Prof. Dr. Albert Dahan|
|- Sponsor/Initiator ||Leiden University Medical Center (LUMC), Department of Anaesthesiology|
(Source(s) of Monetary or Material Support)
|TREND Delft |
|- Brief summary||The NMDA-receptor antagonist ketamine, at relatively low-dose, is a potent analgesic. It is used in the perioperative setting as well as in chronic pain, for example in the treatment of neuropathic pain and pain from malignancies. We are currently assessing ketamine’s analgesic efficacy in CRPS type 1 patients in an experimental study (protocol P05.100).
Despite its wide use, relatively little is knows about ketamine’s pharmacokinetics –PK– and pharmacodynamics –PD– or the link between the two. For example, there is no knowledge on the link parameter ke0, which is an estimate of the drugs onset and offset-times. Knowledge of ketamine’s PK and PD is needed to be able to fully understand clinical ketamine data in patients, such as CRPS type 1 patients. Furthermore, it will enable the optimization of infusion schemes and hence the treatment of patients on ketamine.
Ketamine is a racemic mixture. Recently the S(+) form became available (Ketanest). In contrast to the racemic mixture, S(+)-ketamine shows less psychomimetic side effects. This is the reason that the S(+) form is now widely used with the racemic mixture rapidly loosing market.
In this study we will assess the pharmocokinetics and pharmacodynamics of intravenous S(+)-ketamine in healthy volunteers. This will result in a pharmacokinetic/pharmaco-dynamic (PK/PD) model which may be used to predict S(+)-ketamine concentration and pain relief after intravenous infusion.
The PK of S(+)-ketamine will be studied by obtaining arterial blood samples at regular times after iv infusion. The PD of S(+)-ketamine will focus on pain relief and the side effect profile, with special emphasis on psychomimetic side effects and blood pressure.
The design of the study is placebo-controlled, single-blind, randomized cross-over.
Aims of the study:
1) To obtain pharmacokinetic parameters of S(+)-ketamine;
2) To study the pharmacodynamic effects of intravenous S(+)-ketamine on experimental pain;
3) To study the pharmacodynamic effects of intravenous S(+)-ketamine using Bowdle scales.
|- Main changes (audit trail)|
|- RECORD||30-mei-2006 - 26-feb-2007|